Toward a molecular design of porous carbon materials

1. Download high-res image (84KB)
2. Download full-size image

     

基于A位元素置换策略合成新型MAX相材料Ti3ZnC2

MAX相材料是一类兼具金属和陶瓷特性的三元层状材料, 在高温导电、耐磨、耐腐蚀和耐辐照损伤等方面性能优异。目前已经合成出的MAX相材料已有70余种, 但A位元素一直局限在ⅢA和ⅣA主族元素, 如Al、Si、Ga等, 而以副族元素占据A位的MAX相鲜有报道。本研究以Ti₃AlC₂为前驱体, 利用熔盐中的A位置换反应, 制备出了A位为Zn元素的全新MAX相材料Ti₃ZnC₂。结合X射线衍射、扫描电子显微镜和透射电子显微镜等分析手段对Ti₃ZnC₂的成分和结构进行了确认, 并通过密度泛函理论对Ti₃ZnC₂的结构稳定性和晶格参数进行了确定。进一步通过热力学计算对Fe、Co、Ni、Cu等几种元素的A位置换反应进行了预测, 发现采用这几种元素的氧化物进行置换反应在热力学上也都具有可行性。本研究所提出的元素置换策略是在保持MAX相六方层状晶体结构的基础上, 利用Al、Zn在高温下形成共晶产物实现Zn原子向A层内的迁移, 而熔盐介质的存在促进了反应动力学。本方法巧妙地避免了MAX相传统合成过程中竞争相的形成, 如M-A合金相, 因此可以用于探索更多未知的MAX相材料。     

The Potential Role of SP-G as Surface Tension Regulator in Tear Film: From Molecular Simulations to Experimental Observations

The ocular surface is in constant interaction with the environment and with numerous pathogens. Therefore, complex mechanisms such as a stable tear film and local immune defense mechanisms are required to protect the eye. This study describes the detection, characterization, and putative role of surfactant protein G (SP-G/SFTA2) with respect to wound healing and surface activity. Bioinformatic, biochemical, and immunological methods were combined to elucidate the role of SP-G in tear film. The results show the presence of SP-G in ocular surface tissues and tear film (TF). Increased expression of SP-G was demonstrated in TF of patients with dry eye disease (DED). Addition of recombinant SP-G in combination with lipids led to an accelerated wound healing of human corneal cells as well as to a reduction of TF surface tension. Molecular modeling of TF suggest that SP-G may regulate tear film surface tension and improve its stability through specific interactions with lipids components of the tear film. In conclusion, SP-G is an ocular surface protein with putative wound healing properties that can also reduce the surface tension of the tear film.     

ILB®, a Low Molecular Weight Dextran Sulphate,Restores Glutamate Homeostasis,Amino Acid Metabolism and Neurocognitive Functions in a Rat Model of Severe Traumatic Brain Injury

In a previous study, we found that administration of ILB^®, a new low molecular weight dextran sulphate, significantly improved mitochondrial functions and energy metabolism, as well as decreased oxidative/nitrosative stress, of brain tissue of rats exposed to severe traumatic brain injury (sTBI), induced by the closed-head weight-drop model of diffused TBI. Using aliquots of deproteinized brain tissue of the same animals of this former study, we here determined the concentrations of 24 amino acids of control rats, untreated sTBI rats (sacrificed at 2 and 7 days post-injury) and sTBI rats receiving a subcutaneous ILB^® administration (at the dose levels of 1, 5 and 15 mg/kg b.w.) 30 min post-impact (sacrificed at 2 and 7 days post-injury). Additionally, in a different set of experiments, new groups of control rats, untreated sTBI rats and ILB^®-treated rats (administered 30 min after sTBI at the dose levels of 1 or 5 mg/kg b.w.) were studied for their neurocognitive functions (anxiety, locomotor capacities, short- and long-term memory) at 7 days after the induction of sTBI. Compared to untreated sTBI animals, ILB^® significantly decreased whole brain glutamate (normalizing the glutamate/glutamine ratio), glycine, serine and γ-aminobutyric acid. Furthermore, ILB^® administration restored arginine metabolism (preventing nitrosative stress), levels of amino acids involved in methylation reactions (methionine, L-cystathionine, S-adenosylhomocysteine), and N-acetylaspartate homeostasis. The macroscopic evidences of the beneficial effects on brain metabolism induced by ILB^® were the relevant improvement in neurocognitive functions of the group of animals treated with ILB^® 5 mg/kg b.w., compared to the marked cognitive decline measured in untreated sTBI animals. These results demonstrate that ILB^® administration 30 min after sTBI prevents glutamate excitotoxicity and normalizes levels of amino acids involved in crucial brain metabolic functions. The ameliorations of amino acid metabolism, mitochondrial functions and energy metabolism in ILB^®-treated rats exposed to sTBI produced significant improvement in neurocognitive functions, reinforcing the concept that ILB^® is a new effective therapeutic tool for the treatment of sTBI, worth being tested in the clinical setting.